{"id":"eht-0202-etazolate","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"20%","effect":"Headache"},{"rate":"15%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Etazolate acts by inhibiting the enzyme phosphodiesterase, leading to increased levels of cyclic AMP (cAMP) in the brain, which can help to reduce anxiety and hallucinations.","oneSentence":"Etazolate is a phosphodiesterase inhibitor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:59:26.758Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety"},{"name":"Hallucinations"}]},"trialDetails":[{"nctId":"NCT00880412","phase":"PHASE2","title":"A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Exonhit","startDate":"2008-04","conditions":"Alzheimer's Disease","enrollment":197}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EHT 0202","etazolate"],"phase":"phase_2","status":"active","brandName":"EHT 0202 etazolate","genericName":"EHT 0202 etazolate","companyName":"Exonhit","companyId":"exonhit","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etazolate is a phosphodiesterase inhibitor. Used for Anxiety, Hallucinations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}